Physicists push new Parkinson's treatment toward clinical trials

Advancells provides stem cell therapies to fight various diseases

An assistive technology for people with ALS

Microchips that release therapeutics inside the body

An implantable, microchip-based device that may soon replace the injections and pills now needed to treat chronic diseases has been developed by MIT spinoff Microchips Biotech. The microchips consist of hundreds of pinhead-sized reservoirs, each capped with a metal membrane, that store tiny doses of therapeutics or chemicals. An electric current delivered by the device removes the membrane, releasing a single dose. The device can be programmed wirelessly to release individual doses for up to 16 years to treat, for example, diabetes (lat. Diabetes Mellitus), cancer (lat. Carcinoma), multiple sclerosis (lat. Sclerosis multiplex), and osteoporosis.

by
2 days ago

Deep Genomics: creating genetic medicines with AI

Deep Genomics has built a biologically accurate machine learning platform that supports geneticists, molecular biologists, chemists, toxicologists and drug developers in the identification and development of genetic medicines and gene therapies. The platform leverages automation and is based on the most advanced knowledge and data in experimental biology, genetics, medicine and therapeutics. Launched in 2015, Deep Genomics has 27 employees with advanced degrees and extensive industry experience in artificial intelligence, automation, software engineering, genomics, molecular and cell biology, human genetics, molecular diagnostics, and organic chemistry. It is located in the heart of Toronto, the fastest growing tech hub in North America and one of the most livable cities in the world, next to four research hospitals, three medical research institutes, and the AI research labs of Google, Uber and the Vector Institute for Artificial Intelligence.

by
2 days ago

Orgenesis provides innovative cell therapies

Orgenesis is a vertically-integrated biopharmaceutical company with expertise and unique experience in cell therapy development and manufacturing. Through its Israeli subsidiary, Orgenesis Ltd., Orgenesis is developing technology designed to successfully reprogram human liver cells into glucose-responsive, fully functional, IPCs. Orgenesis believes that converting the diabetic patient's own tissue into insulin-producing cells has the potential to overcome the significant issues of donor shortage, cost and exposure to chronic immunosuppressive therapy associated with islet cell transplantation. Through its Belgian subsidiary, MaSTherCell S.A., a global Contract Development and Manufacturing Organization (CDMO), Orgenesis is able to deliver optimized process industrialization capacities to cell therapy organizations, and speed up the arrival of their therapies onto the market. This integrated approach supports the Company's business philosophy of bringing to market significant life-improving medical treatments.  

by
2 days ago

Biofeedback Technology Helps Improve Balance in Parkinson’s Patients

Gemini Therapeutics: the precision medicine for genetic diseases

A miniaturized system that can treat neurological disorders

An innovative clay-based antimicrobial packaging

A packaging film coated with clay nanotubes, developed as part of a TÜBİTAK ARDEB 1003 project by Sabancı University Nanotechnology Research and Application Center (SUNUM) Researcher Hayriye Ünal as implementer and Sabancı University Faculty of Engineering and Natural Sciences Dean Yusuf Menceloğlu, Sabancı University Faculty of Engineering and Natural Sciences Member Fevzi Çakmak Cebeci and Integrated Manufacturing Technologies Research and Development Center (TÜMER) Researcher Serkan Ünal as advisors was presented at the 254th National Meeting & Exposition of the American Chemical Society (ACS) in Washington, D.C.

by
2 days ago

Promising Alzheimer's treatment moves toward clinical trials

A new natural treatment for Alzheimer’s disease (lat. morbus Alzheimerianus) has been developed by Muraleedharan Nair, Michigan State University natural products chemist. This will be a major step forward as there is nothing on the market that slows the progression of Alzheimer’s. Dr. Nair has patented a botanical compound, withanamides. His spinoff company, Natural Therapeutics, will begin the trials as soon as funding is in place. This particular research has focused on Ashwagandha, an herbal remedy that’s been used in Eastern medicines for centuries. The researcher's compound withanamides may work to prevent Alzheimer’s disease at the onset, and it also could prevent its progression.

by
3 days ago

New antibiotic combinations for tuberculosis treatment

According to WHO, tuberculosis (TB) is caused by bacteria (Mycobacterium tuberculosis) that most often affect the lungs. Despite the fact that tuberculosis (lat. Phthisis) is curable and preventable, it is one of the top 10 causes of death worldwide. In 2017, 10 million people fell ill with TB, and 1.6 million died from the disease (including 0.3 million among people with HIV). However, new antibiotic combinations for tuberculosis treatment were discovered in a joint project between Sabancı University (SABANCI) and Harvard University. The study also devised a novel method for finding drug combinations with more than two drugs.

by
3 days ago

Cookies help us deliver our Services. By using our website or clicking I agree, you agree to our use of cookies. Learn more about our cookie and privacy policy.

I AGREE

SPINOFF.COM HELPS YOU WITH:

100% Free of Cost For Scientists:

  • One hour of USA/EU attorney consulting
  • 24/7 support of 24 in-house professionals
  • 10 GB space for every scientist (own German Servers)
  • Syndicates with the leading professionals
  • 2,000 000 views of top spinoff are guaranteed
  • The largest DB of professional Investors - over 30.000

100% Free of Cost For Investors:

  • Investment information on 8,000+ spinoffs per year
  • All documents in one place (after NDA)
  • Testimonials from Key Opinion Leaders
  • AI-SDB hides irrelevant spinoffs - saved time up to 90% 
  • One-Click-Reports (OCRs) in own tailored design (PDF)

100% Free of Cost For Universities:

  • Professional Science Spinoff University Report (PDF)
  • No Links to Spinoff.com - Ready to Print and Share
  • Professional dossiers on over 27Tsd VC/PE/FO/ML
  • Professional dossiers on over 3Tsd MNC